While GLP-1 agonists like Semaglutide and Tirzepatide show promising results in weight loss and managing obesity-related conditions, their specific impact on lipedema requires more research
As it consumes mucus, it stimulates the goblet cells in your intestinal lining to produce more
61 A randomised, single-blind, placebo-controlled, single centre phase I study in healthy male volunteers to assess the safety, tolerability, and pharmacokinetics of azd2820 after single ascending doses
However, despite the solid scientific background linking vagal activity and obesity, extensively described in the previous sections, the EMPOWER study yelded negative results: vagal blockade induced a similar weight loss than the control group, which had the same device with a lower charge delivery
If you are already lean and not trying to lose much fat, the chance of meaningful benefit is small